Insider Buying: OPKO Health, Inc. (NASDAQ:OPK) CEO Acquires 100,000 Shares of Stock

OPKO Health, Inc. (NASDAQ:OPKGet Free Report) CEO Phillip Md Et Al Frost bought 100,000 shares of the business’s stock in a transaction dated Thursday, May 23rd. The shares were bought at an average price of $1.27 per share, with a total value of $127,000.00. Following the purchase, the chief executive officer now owns 211,232,222 shares in the company, valued at approximately $268,264,921.94. The transaction was disclosed in a filing with the SEC, which can be accessed through this link.

Phillip Md Et Al Frost also recently made the following trade(s):

  • On Friday, May 17th, Phillip Md Et Al Frost purchased 163,997 shares of OPKO Health stock. The stock was purchased at an average price of $1.29 per share, with a total value of $211,556.13.
  • On Monday, March 18th, Phillip Md Et Al Frost acquired 500,000 shares of OPKO Health stock. The stock was bought at an average cost of $0.87 per share, with a total value of $435,000.00.
  • On Thursday, March 14th, Phillip Md Et Al Frost bought 500,000 shares of OPKO Health stock. The shares were acquired at an average price of $0.89 per share, with a total value of $445,000.00.
  • On Tuesday, March 12th, Phillip Md Et Al Frost bought 600,000 shares of OPKO Health stock. The stock was bought at an average cost of $0.93 per share, with a total value of $558,000.00.
  • On Wednesday, February 28th, Phillip Md Et Al Frost acquired 500,000 shares of OPKO Health stock. The shares were bought at an average price of $0.99 per share, with a total value of $495,000.00.

OPKO Health Trading Down 3.0 %

Shares of OPKO Health stock traded down $0.04 on Thursday, reaching $1.28. 2,785,251 shares of the company’s stock were exchanged, compared to its average volume of 11,264,729. The firm’s 50-day moving average is $1.22 and its two-hundred day moving average is $1.22. The company has a market capitalization of $892.15 million, a P/E ratio of -3.66 and a beta of 1.81. The company has a debt-to-equity ratio of 0.27, a quick ratio of 1.62 and a current ratio of 1.91. OPKO Health, Inc. has a 52 week low of $0.85 and a 52 week high of $2.24.

OPKO Health (NASDAQ:OPKGet Free Report) last issued its earnings results on Tuesday, May 7th. The biotechnology company reported ($0.12) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.09) by ($0.03). The firm had revenue of $173.70 million during the quarter, compared to the consensus estimate of $182.99 million. OPKO Health had a negative return on equity of 17.89% and a negative net margin of 31.44%. OPKO Health’s revenue for the quarter was down 26.9% on a year-over-year basis. During the same quarter in the prior year, the business earned ($0.02) earnings per share. Sell-side analysts predict that OPKO Health, Inc. will post -0.35 EPS for the current fiscal year.

Institutional Investors Weigh In On OPKO Health

Hedge funds have recently made changes to their positions in the business. Invesco Ltd. increased its position in shares of OPKO Health by 300.4% during the third quarter. Invesco Ltd. now owns 5,164,180 shares of the biotechnology company’s stock valued at $8,263,000 after buying an additional 3,874,519 shares during the period. PFG Investments LLC bought a new position in shares of OPKO Health in the first quarter worth approximately $1,125,000. Assenagon Asset Management S.A. boosted its position in OPKO Health by 107.2% during the 1st quarter. Assenagon Asset Management S.A. now owns 1,253,808 shares of the biotechnology company’s stock valued at $1,502,000 after buying an additional 648,569 shares during the period. Charles Schwab Investment Management Inc. grew its holdings in OPKO Health by 7.9% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 5,549,946 shares of the biotechnology company’s stock worth $8,880,000 after acquiring an additional 405,106 shares during the last quarter. Finally, Connor Clark & Lunn Investment Management Ltd. increased its position in shares of OPKO Health by 30.0% in the third quarter. Connor Clark & Lunn Investment Management Ltd. now owns 1,419,957 shares of the biotechnology company’s stock valued at $2,272,000 after acquiring an additional 327,836 shares during the period. 64.63% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

Several analysts have recently weighed in on OPK shares. StockNews.com upgraded OPKO Health to a “sell” rating in a report on Thursday, May 16th. HC Wainwright restated a “buy” rating and issued a $3.00 price target on shares of OPKO Health in a research report on Wednesday, May 8th. Piper Sandler reiterated an “overweight” rating and set a $5.00 price target on shares of OPKO Health in a report on Monday, April 1st. Finally, Barrington Research restated an “outperform” rating and issued a $1.50 price objective on shares of OPKO Health in a report on Monday, April 1st.

Check Out Our Latest Report on OPK

OPKO Health Company Profile

(Get Free Report)

OPKO Health, Inc, a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test.

Read More

Insider Buying and Selling by Quarter for OPKO Health (NASDAQ:OPK)

Receive News & Ratings for OPKO Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OPKO Health and related companies with MarketBeat.com's FREE daily email newsletter.